|
Introduction:
Oligo GEArray is a new oligonucleotide-based gene
expression array platform from SABiosciences Corporation. It combines
a cutting-edge experimentally verified computer algorithm for oligo design
with the high-binding capacity of nylon membranes. The Oligo GEArray also
takes full advantage of up-to-date pathway and gene function information.
Furthermore, the platform also includes a new universal linear RNA
amplification technology, TrueLabeling-AMP™, specially developed and
optimized for the Oligo GEArray. This article reviews the Oligo GEArray by
summarizing its features and performance.
1. Features of the Oligo GEArray:
The Oligo GEArray contains one 60-mer 3' biased oligo for each gene in a
low-density pathway-or application-specific list containing either 100, 250,
or 440 genes. A rigorous bioinformatic algorithm evaluates each potential
gene-specific oligo probes. The best and chosen probe satisfies a number of
criteria such as specificity, sequence complexity, secondary structure,
melting temperature, distance to 3' end of the transcript and GC content. The
Oligo GEArray production process prints these oligo probes on a positively
charged 3D nylon matrix. Compared to hard surfaces like glass slide, nylon
membranes provide a larger probe immobilization, target hybridization and
detection surface. The Oligo GEArray utilizes an easier and more
cost-effective version of standard RNA amplification and labeling technology
to work specifically with the 3' end biased oligo array. Also, the system
takes advantage of a time-tested chemiluminescence detection system and a new
fluorescent detection method, both optimized for nylon microarrays. All of
these characteristics allow the Oligo GEArray to offer the best possible
balance of system performance, convenience and cost effectiveness. The
important features of the Oligo GEArray are summarized in Table 1.
| Table 1: Summary of Oligo GEArray Features |
| System Features |
|
| Array Design |
Pathway or application focused gene grouping. Array density
from 100-440 genes per array. Includes specially designed control features.
|
| Probe Design |
mRNA 3' end biased 60mer oligonucleotide (Median distance ~160
bases from 3' end)
|
| Array matrix |
Positively charged nylon membrane
|
| Target labeling |
One-tube proprietary IVT based linear RNA amplification &
labeling kit
|
| Recommended Detection Method |
Single color chemiluminescent detection
|
| Alternative Detection Method |
Single color fluorescent detection
|
| Cost |
Per Array $ 50 to 100 (US List Price)
|
2. Performance of the Oligo GEArray: With the
combination of a 3D nylon matrix, an improved RNA linear amplification and
labeling method and chemiluminescent detection, the Oligo GEArray® system
delivers performance comparable to other microarrays. To characterize system
performance more closely, a series of hybridization experiments has been
performed with known quantities of labeled synthetic RNA target spiked into a
labeled human RNA sample. The Oligo GEArray detects the target in the 10 fM
range (Figure 1) at a spiking ratio of 1:20,000,000. The signal for the
synthetic target also displays a linear response over three orders of
magnitude range of concentration. The low limit of detection and wide linear
response range allows the Oligo GEArray to detect low abundance transcripts.
|

|
|
Figure 1. The Oligo GEArray has a LOD of 10 fM and a dynamic range
of 0.01 pM - 10 pM in a controlled spiking experiment.
|
Manufacture of the Oligo GEArrays utilizes an advanced
non-contact inkjet type printing process that ensures good array printing
quality and reproducibility. Figure 2 displays a representative comparison
between two hybridization replicates. The typical median percent Coefficient
of Variation is routinely less than 10. Table 2 summarizes the performance of
the Oligo GEArray.
 |
| Figure 2: The Oligo GEArray® exhibits excellent array-to-array
reproducibility. XpressRef™ Human Universal Reference Total RNA
(GA-004) was converted to labeled cRNA target using the TrueLabeling-AMP™
Linear RNA Amplification Kit (GA-010). Equal amounts (2 µg) of
amplified product was hybridized to separate Human Oligo GEArray®
Trial Microarrays. The Chemiluminescent Detection Kit (D-01) was used
to detect the presence of labeled target on the arrays. The raw
intensity values for each gene from one array were plotted against
those values from the second array, and the data were fit to a
straight line having a correlation factor (R2) of 0.9939. The result
demonstrates that raw Oligo GEArray® data is very reproducible from
one array to the next.
|
| Table 2. Typical System Performance |
|
Typical Performance |
| Sensitivity |
Capable of detecting 10 fM of synthetic target. (Mass ratio
< 1:20,000,000) |
| Linear Dynamic Range |
> 3 orders of magnitude (0.01 - 10 pM) |
| Specificity |
Discrimination of 6/60 base mismatch (90% homology) |
| Reproducibility |
~ 10% CV |
| Sample Input |
100 ng - 3 µg total RNA |
3. Target Amplification & Labeling:
In vitro transcription based RNA amplification methods
have been used for many microarray platforms. The method provides excellent
amplification power while preserving the original transcript profile.
Amplification allows the use the smaller amounts of input RNA and the
detection of lower abundance messages. However, the current methods are both
time-consuming and costly. SABiosciences has designed an easier and more cost
effective method for the Oligo GEArray, the TrueLabeling-Amp Linear RNA
Amplification Kit. The protocol requires only one tube reaction and only one
purification step and occurs in less than six hours. This method delivers
expression profiles nearly identical to those generated using the
traditional, longer, more tedious and more expensive procedures (Figure 3).
The TrueLabeling-Amp Linear RNA Amplification Kit is an integral part of the
Oligo GEArray system providing it with excellent amplification performance.
Table 3 summarizes the characteristics of the TrueLabeling-Amp Linear RNA
Amplification Kit.
|

|
| Figure 3. The TrueLabeling-AMP and the traditional IVT method
generate similar gene expression profiles. XpressRef™ Human
Universal Reference Total RNA (1 µg, GA-004) was converted to labeled
cRNA target using the TrueLabeling-AMP™ Linear RNA Amplification Kit
(GA-010) or a traditional IVT method. Equal amounts (4 µg) of amplified
product was hybridized to separate Oligo GEArray® Human Cancer
Microarrays (OHS-802). The Chemiluminescent Detection Kit (D-01) was
used to detect the presence of labeled target on the arrays. The raw
intensity values for each gene as determined by the two methods were
plotted against on another, and the data were fit to a straight line
having a correlation factor (R2) of 0.9729. The result demonstrates that
the more convenient and the more tedious target amplification methods
yield similar gene expression profiles.
|
| Table 3. Comparison of Target Synthesis and Labeling
Methods |
| Typical Total RNA Input |
0.1-3 µg |
0.1-10 µg |
| Labeled Products |
Linear amplified cRNA, 3' end biased |
Linear amplified cRNA, 3' end biased |
| Time Consideration |
5 ˝ hour |
1 ˝ - 2 Day |
| Procedure |
Single vial, 2 step reaction |
Multi-step procedure |
| Cost Per Reaction |
< $30 |
>$65 |
4. Array Detection Options:
The Chemiluminescent Detection Kit from SABiosciences already provides sensitive
detection for both its Oligo GEArrays and cDNA GEArrays. The GEArray
microarray system requires no special equipment and offers flexible detection
options. The chemiluminescent detection method permits the use of either
highly sensitive cooled CCD camera based imagers or basic X-ray film to
record array images. Methodology is now available for the single-color
fluorescent detection of the GEArray. Briefly, streptavidin conjugated to the
Cy5 fluorophore replaces the alkaline phosphatase conjugate normally used for
chemiluminescence. The GEArray is then dried and mounted on a glass slide.
The slide-mounted GEArray can be analyzed on any commercial fluorescent
scanner. The fluorescent and chemiluminescent detection methods yield nearly
identical gene expression profiles (Figure 4).
Figure 4. The Fluorescent and Chemiluminescent Detection Methods give
similar GEArray results. XpressRef™ Human Universal Reference Total RNA
(GA-004) was converted to labeled cRNA target using the TrueLabeling-AMP™
Linear RNA Amplification Kit (GA-010). Equal amounts of amplified product was
hybridized to separate Oligo GEArray® Human Hematology Microarrays
(OHS-801). Either the Chemiluminescent Detection Kit (D-01) (Right Image,
acquired with an Alpha Innotech FluorChem 8800 CCD camera) of the fluorescent
method of detection (Left Image, scanned on an Axon 4000B instrument) was
used to detect the presence of labeled target on the arrays. The result
indicates that both detection methods yield similar gene expression profiles.
Summary:
The Oligo GEArray represents each gene in its application- and
pathway-specific gene lists with a carefully designed gene-specific
oligonucleotide. The use of oligos, as opposed to gene-specific cDNA
fragments for example, permits faster development of microarray content and
potentially increases the specificity of target hybridization and the
resulting array signal. Characteristics common between the Oligo and cDNA
GEArray include the high-binding capacity of the nylon membrane and the
Chemiluminescent Detection Method. When also combined with the new
TrueLabeling-AMP Linear RNA Amplification Kit, all of these properties help
provide the Oligo GEArray systems with sensitivity, wide dynamic ranges, and
reproducibility comparable to all other microarray platforms. The
TrueLabeling-AMP method also imparts to the Oligo GEArray the ability to
detect lower abundance messages using smaller amounts of input RNA in a time
and cost effective manner. The increased convenience of the labeling method
does not compromise its ability to provide an equally accurate representation
of RNA samples as the traditional methods. Finally, the development of a
fluorescent method of detection increases the flexibility of the Oligo
GEArray platform. In these ways, the Oligo GEArray further advances the state
of microarray technology.
|